Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jan 1;63(1):88-93.
doi: 10.1097/SHK.0000000000002481.

ANGIOTENSIN II FOR CATECHOLAMINE-RESISTANT VASODILATORY SHOCK IN PATIENTS WITH ACUTE KIDNEY INJURY: A POST HOC ANALYSIS OF THE ATHOS-3 TRIAL

Anis Chaba, Alexander Zarbock  1 , Lui G Forni  2 , Johanna Hästbacka  3 , Elena Korneva  4 , Giovanni Landoni  5 , Peter Pickkers  6 , Rinaldo Bellomo
Affiliations
Randomized Controlled Trial

ANGIOTENSIN II FOR CATECHOLAMINE-RESISTANT VASODILATORY SHOCK IN PATIENTS WITH ACUTE KIDNEY INJURY: A POST HOC ANALYSIS OF THE ATHOS-3 TRIAL

Anis Chaba et al. Shock. .

Abstract

Objective: The combination of catecholamine-resistant vasodilatory shock and acute kidney injury (AKI) is associated with high morbidity and mortality. The role of angiotensin II (ANGII) in this setting is unclear. Methods: We conducted a post hoc analysis of the Angiotensin II for the Treatment of High-Output Shock (ATHOS) 3 trial which assessed the effect of Intravenous ANG II or placebo in patients with refractory vasodilatory shock in 75 intensive care units across nine countries in North America, Australasia, and Europe. We included patients with all stages AKI at initiation of ANG II or placebo and assessed 28-day mortality as primary outcome. We studied mean arterial pressure (MAP) response and days alive and free from renal replacement therapy (RRT) up to day 7 as secondary outcome. Results: Of 321 ATHOS-3 patients, 203 (63%) had AKI at randomization, with stage 3 AKI being dominant (67%). Median age was 63 years and median APACHE II score was 30. By day 28, overall, 118 (58%) of patients had died (53% with ANGII vs. 63% with placebo, hazard ratio = 0.75, 95% CI [0.52-1.08], P = 0.121). Among AKI stage 3 patients, however, ANGII was associated with significantly lower mortality (48% vs. 67%, hazard ratio = 0.57, 95% CI [0.36-0.91], P = 0.024). Additionally, in this subgroup, compared with placebo, patients receiving ANGII were more likely to achieve a MAP response (P < 0.001) and had more days alive and free from RRT (P < 0.001). Conclusions: Compared with placebo, in patients with catecholamine-resistant vasodilatory shock and stage 3 AKI, ANGII is associated with lower 28-day, greater likelihood of MAP response, and more days alive and free from RRT. These findings support the conduct of future ANGII trials in patients with stage 3 AKI.

Trial registration: ClinicalTrials.gov NCT00233884.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: R.B. reports receiving research grants, speaking engagement fees and advisory board fees from Paion, Viatris, La Jolla, Baxter Healthcare, and Jafron Healthcare. A.Z. reports receiving advisory board fees from Paion and VIATRIS. A.C. reports no conflict of interest. L.F. reports advisory board fees and lecture fees from Paion. J.H. reports receiving advisory board fees from Paion. E.K. reports working for Paion. G.L. reports receiving advisory board fees from VIATRIS. P.P. reports receiving advisory board fees from Paion.

References

    1. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med . 2021;47(11):1181–1247.
    1. Brown SM, Lanspa MJ, Jones JP, et al. Survival after shock requiring high-dose vasopressor therapy. Chest . 2013;143(3):664–671.
    1. Landry GJ, Mostul CJ, Ahn DS, et al. Causes and outcomes of finger ischemia in hospitalized patients in the intensive care unit. J Vasc Surg . 2018;68(5):1499–1504.
    1. Wieruszewski ED, Jones GM, Samarin MJ, et al. Predictors of dysrhythmias with norepinephrine use in septic shock. J Crit Care . 2021;61:133–137.
    1. Sacha GL, Lam SW, Wang L, et al. Association of catecholamine dose, lactate, and shock duration at vasopressin initiation with mortality in patients with septic shock*. Crit Care Med . 2022;50(4):614–623.

Publication types

Associated data